Literature DB >> 28164774

Tauopathies - Focus on Changes at the Neurovascular Unit.

Alena Michalicova1, William A Banks2, Jaroslav Legath3, Andrej Kovac4.   

Abstract

In the past, the blood-brain barrier (BBB) has been characterized mainly as a layer of endothelial cells forming the vessel/capillary wall of the brain. More recently, the BBB is considered to be a part of a highly dynamic and interactive system called the neurovascular unit (NVU), consisting of vascular cells, glial cells, and neurons. The list of central nervous system (CNS) pathologies involving BBB dysfunction is rapidly growing. The opening of the BBB and subsequent infiltration of serum components to the brain can lead to a host of processes resulting in progressive synaptic and neuronal dysfunction and loss. Such processes have been implicated in different diseases, including vascular dementias, stroke, Alzheimer´s disease (AD), Parkinson´s disease, multiple sclerosis, amyotrophic lateral sclerosis, hypoxia, ischemia, and diabetes mellitus. Tauopathies represent a heterogeneous group of around 20 different neurodegenerative diseases characterized by abnormal deposition of microtubule-associated protein tau in cells of the nervous system. Increased microvascular permeability has been more typically related to cerebrovascular deposition of amyloid-β (Aβ), but in contrast very little is known about the connection between functional impairment of the BBB and the misfolded tau proteins. Here, we review what is known about tauopathies, the BBB, and the NVU. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease; Tauopathies; blood-brain barrier; neurovascular unit; tau protein

Mesh:

Year:  2017        PMID: 28164774     DOI: 10.2174/1567205014666170203143336

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  13 in total

1.  Cerebrovascular inflammation is associated with tau pathology in Guam parkinsonism dementia.

Authors:  Petra Majerova; Ralph M Garruto; Andrej Kovac
Journal:  J Neural Transm (Vienna)       Date:  2018-04-26       Impact factor: 3.575

2.  Metabolic status of CSF distinguishes rats with tauopathy from controls.

Authors:  Radana Karlíková; Kateřina Mičová; Lukáš Najdekr; Alžběta Gardlo; Tomáš Adam; Petra Majerová; David Friedecký; Andrej Kováč
Journal:  Alzheimers Res Ther       Date:  2017-09-21       Impact factor: 6.982

3.  Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies.

Authors:  Petra Majerova; Alena Michalicova; Martin Cente; Jozef Hanes; Jozef Vegh; Agnes Kittel; Nina Kosikova; Viera Cigankova; Sandra Mihaljevic; Santosh Jadhav; Andrej Kovac
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

Review 4.  Proteomic and Genomic Changes in Tau Protein, Which Are Associated with Alzheimer's Disease after Ischemia-Reperfusion Brain Injury.

Authors:  Marzena Ułamek-Kozioł; Stanisław Jerzy Czuczwar; Sławomir Januszewski; Ryszard Pluta
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

5.  Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains.

Authors:  Luis O Soto-Rojas; B Berenice Campa-Córdoba; Charles R Harrington; Andrés Salas-Casas; Mario Hernandes-Alejandro; Ignacio Villanueva-Fierro; Marely Bravo-Muñoz; Linda Garcés-Ramírez; Fidel De La Cruz-López; Miguel Ángel Ontiveros-Torres; Goar Gevorkian; Mar Pacheco-Herrero; José Luna-Muñoz
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 6.  The Neurovascular Unit Dysfunction in Alzheimer's Disease.

Authors:  Luis O Soto-Rojas; Mar Pacheco-Herrero; Paola A Martínez-Gómez; B Berenice Campa-Córdoba; Ricardo Apátiga-Pérez; Marcos M Villegas-Rojas; Charles R Harrington; Fidel de la Cruz; Linda Garcés-Ramírez; José Luna-Muñoz
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 7.  Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link.

Authors:  Jaime Ramos-Cejudo; Thomas Wisniewski; Charles Marmar; Henrik Zetterberg; Kaj Blennow; Mony J de Leon; Silvia Fossati
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

Review 8.  Tau Protein Dysfunction after Brain Ischemia.

Authors:  Ryszard Pluta; Marzena Ułamek-Kozioł; Sławomir Januszewski; Stanisław J Czuczwar
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  Shared Genomic and Proteomic Contribution of Amyloid and Tau Protein Characteristic of Alzheimer's Disease to Brain Ischemia.

Authors:  Ryszard Pluta; Marzena Ułamek-Kozioł; Sławomir Januszewski; Stanisław J Czuczwar
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 6.208

Review 10.  SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.

Authors:  Mercedes Unzeta; Mar Hernàndez-Guillamon; Ping Sun; Montse Solé
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.